Anterogen.Co.Ltd (065660) - Net Assets

Latest as of September 2025: ₩90.04 Billion KRW ≈ $61.02 Million USD

Based on the latest financial reports, Anterogen.Co.Ltd (065660) has net assets worth ₩90.04 Billion KRW (≈ $61.02 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩91.44 Billion ≈ $61.97 Million USD) and total liabilities (₩1.40 Billion ≈ $951.49K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Anterogen.Co.Ltd (065660) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩90.04 Billion
% of Total Assets	98.46%
Annual Growth Rate	23.86%
5-Year Change	35.95%
10-Year Change	562.36%
Growth Volatility	30.98

Anterogen.Co.Ltd - Net Assets Trend (2014–2024)

This chart illustrates how Anterogen.Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 065660 total asset value for the complete picture of this company's asset base.

Annual Net Assets for Anterogen.Co.Ltd (2014–2024)

The table below shows the annual net assets of Anterogen.Co.Ltd from 2014 to 2024. For live valuation and market cap data, see 065660 market cap overview.

Year	Net Assets	Change
2024-12-31	₩110.21 Billion ≈ $74.69 Million	-14.86%
2023-12-31	₩129.44 Billion ≈ $87.72 Million	+21.21%
2022-12-31	₩106.79 Billion ≈ $72.37 Million	-8.62%
2021-12-31	₩116.87 Billion ≈ $79.20 Million	+44.16%
2020-12-31	₩81.07 Billion ≈ $54.94 Million	+18.53%
2019-12-31	₩68.39 Billion ≈ $46.35 Million	+21.97%
2018-12-31	₩56.07 Billion ≈ $38.00 Million	+20.31%
2017-12-31	₩46.61 Billion ≈ $31.58 Million	+36.98%
2016-12-31	₩34.02 Billion ≈ $23.06 Million	+104.48%
2015-12-31	₩16.64 Billion ≈ $11.28 Million	+28.38%
2014-12-31	₩12.96 Billion ≈ $8.78 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Anterogen.Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 459682081000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	₩120.64 Billion	109.46%
Total Equity	₩110.21 Billion	100.00%

Anterogen.Co.Ltd Competitors by Market Cap

The table below lists competitors of Anterogen.Co.Ltd ranked by their market capitalization.

Company	Market Cap
Dynamic Cables Limited NSE:DYCL	$194.13 Million
AgriFORCE Growing Systems Ltd NASDAQ:AGRI	$194.14 Million
Hong Leong Capital Bhd KLSE:5274	$194.17 Million
Windlas Biotech Limited NSE:WINDLAS	$194.17 Million
Polaris Infrastructure Inc TO:PIF	$193.99 Million
Solara Active Pharma Sciences Limited NSE:SOLARA	$193.95 Million
Michlol Finance Ltd TA:MCLL	$193.91 Million
Greenx Metals Ltd AU:GRX	$193.85 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Anterogen.Co.Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 129,444,936,990 to 110,211,616,140, a change of -19,233,320,850 (-14.9%).
Net loss of 2,292,835,490 reduced equity.
Other factors decreased equity by 16,940,485,360.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-2.29 Billion	-2.08%
Other Changes	₩-16.94 Billion	-15.37%
Total Change	₩-	-14.86%

Book Value vs Market Value Analysis

This analysis compares Anterogen.Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.18x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 7.90x to 3.18x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩4558.73	₩36000.00	x
2017-12-31	₩5859.76	₩36000.00	x
2018-12-31	₩6643.89	₩36000.00	x
2019-12-31	₩7906.52	₩36000.00	x
2020-12-31	₩8914.81	₩36000.00	x
2021-12-31	₩12403.78	₩36000.00	x
2022-12-31	₩10973.93	₩36000.00	x
2023-12-31	₩13301.82	₩36000.00	x
2024-12-31	₩11325.39	₩36000.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Anterogen.Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -2.08%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -33.07%
• Asset Turnover: 0.06x
• Equity Multiplier: 1.05x
Recent ROE (-2.08%) is above the historical average (-3.04%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-10.92%	-77.18%	0.13x	1.12x	₩-2.71 Billion
2015	-0.35%	-1.65%	0.19x	1.11x	₩-1.72 Billion
2016	1.09%	7.59%	0.14x	1.04x	₩-3.03 Billion
2017	0.96%	8.34%	0.09x	1.25x	₩-4.21 Billion
2018	-1.72%	-26.66%	0.04x	1.81x	₩-6.57 Billion
2019	-5.92%	-97.64%	0.05x	1.24x	₩-10.89 Billion
2020	-5.40%	-105.39%	0.04x	1.16x	₩-12.48 Billion
2021	-0.47%	-6.82%	0.06x	1.17x	₩-12.24 Billion
2022	-6.40%	-103.73%	0.05x	1.16x	₩-17.52 Billion
2023	-2.19%	-43.70%	0.04x	1.15x	₩-15.79 Billion
2024	-2.08%	-33.07%	0.06x	1.05x	₩-13.31 Billion

Industry Comparison

This section compares Anterogen.Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $100,225,866,645
Average return on equity (ROE) among peers: 0.62%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Anterogen.Co.Ltd (065660)	₩90.04 Billion	-10.92%	0.02x	$194.04 Million
Sam Chun Dang Pharm. Co. Ltd (000250)	$298.46 Billion	-3.48%	0.37x	$6.03 Billion
DongKoo Bio&Pharma Co. Ltd (006620)	$105.33 Billion	1.93%	1.32x	$33.52 Million
NatureCell Co.Ltd (007390)	$39.48 Billion	-1.17%	0.30x	$688.81 Million
Sam-A Pharm. Co. Ltd (009300)	$110.58 Billion	8.88%	0.25x	$68.66 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$169.03 Billion	11.15%	0.19x	$89.89 Million
WooGene B&G Co. Ltd (018620)	$29.85 Billion	-6.92%	1.60x	$13.13 Million
Oscotec Inc (039200)	$26.33 Billion	-13.85%	0.55x	$990.30 Million
EstechPharma Co. Ltd (041910)	$111.39 Billion	9.84%	0.11x	$59.21 Million
Komipharm International Co. Ltd (041960)	$76.28 Billion	-3.69%	0.60x	$380.81 Million
Eagle Veterinary Technology Co.Ltd (044960)	$35.53 Billion	3.47%	0.29x	$34.35 Million

About Anterogen.Co.Ltd

KQ:065660 Korea Pharmaceuticals

Market Cap

$194.04 Million

₩286.33 Billion KRW

Market Cap Rank

#16652 Global

#717 in Korea

Share Price

₩36000.00

Change (1 day)

-4.26%

52-Week Range

₩19850.00 - ₩58000.00

All Time High

₩197700.00